GDF11
An endogenous TGF-β-superfamily protein at the center of the contested 'young blood' rejuvenation literature — biology real, therapeutic-rejuvenation claims contested.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
GDF11 entered the public conversation through high-profile heterochronic parabiosis studies suggesting it as a circulating 'youth factor.' Subsequent replication efforts have been mixed and the rejuvenation framing is widely contested. The underlying biology — TGF-β family signaling through ActRIIB — remains real and relevant.
- Class
- Endogenous TGF-β superfamily ligand
- Sponsor
- Multiple academic groups; no major pharmaceutical program
- Stage
- Preclinical / contested
- Initial framing
- Circulating 'youth factor' (since contested)
What it is
GDF11 (Growth Differentiation Factor 11) is an endogenous member of the TGF-β superfamily, structurally and functionally related to myostatin (GDF-8). It signals through ActRIIB and Smad2/3 in tissue-specific patterns. The molecule attracted broad attention through the heterochronic parabiosis literature of 2013–2014, which suggested GDF11 as a circulating factor whose decline with age contributes to age-related dysfunction in muscle, heart, and brain — the much-discussed 'young blood rejuvenation' framing.
Current research status
GDF11 remains in academic preclinical research with no advanced pharmaceutical program. The 2014 cluster of high-profile rejuvenation papers (Loffredo et al., Sinha et al., Katsimpardi et al.) was followed by replication failures and substantial controversy about both the assays used to measure circulating GDF11 levels and the interpretation of the parabiosis biology. The current academic consensus is that the simple 'GDF11 declines with age and supplementing it produces rejuvenation' framing is not supported by the totality of evidence.
Mechanistic rationale
Like myostatin, GDF11 signals through ActRIIB and downstream Smad2/3 transcription factors. Tissue-specific developmental and postnatal roles include patterning during embryogenesis, regulation of olfactory neurogenesis, and modulation of cardiac and skeletal muscle biology. Whether circulating GDF11 levels meaningfully decline with age, and whether exogenous supplementation produces rejuvenation effects, are the contested questions.
Available evidence
Original parabiosis/rejuvenation papers (2013–2014) — Loffredo et al. (cardiac hypertrophy reversal), Sinha et al. (skeletal muscle), and Katsimpardi et al. (CNS) reported that systemic GDF11 administration reversed age-related dysfunction in mouse models.[1][2][3]
Replication challenges (Egerman et al., Cell Metab 2015 and subsequent) — Reported that GDF11 levels actually rise rather than fall with age (with the original assays critiqued as non-specific for GDF11 vs. myostatin) and that high-dose GDF11 inhibits rather than promotes muscle regeneration.[4]
The field has been actively debated since, with no clean resolution. The biology of GDF11 itself is real; the rejuvenation-therapy framing is contested.
Why it's interesting
GDF11 is a useful case study in how high-profile preclinical findings can substantially reshape the public understanding of an area before replication efforts complete the picture. The 'young blood' framing has had outsized influence on biotech and biohacker communities. For users following longevity science, understanding the GDF11 controversy is part of understanding how the field evaluates and reweights claims as evidence matures.
Limitations & risks
The therapeutic-rejuvenation framing is contested and not supported by the totality of evidence. Even if administering exogenous GDF11 produced beneficial effects, the TGF-β superfamily ligand pharmacology raises substantial off-target concerns (GDF11 binds the same ActRIIB receptor as myostatin and several other muscle-suppressive ligands). No clinical translation pathway is currently active.
Community discussion notes
GDF11 remains a topic of substantial discussion in biohacker and longevity communities, often accompanied by the original 'young blood' framing without the subsequent replication-controversy context. The absence of a serious clinical program despite years of academic discussion is itself informative.
The takeaway
GDF11 is a real biological molecule whose role in age-related dysfunction was framed in the 2013–2014 literature as a circulating youth factor amenable to therapeutic supplementation. Subsequent replication efforts and assay critiques have left that framing contested. For the current state of evidence, treat the 'GDF11 rejuvenation' hypothesis as preliminary at best — not as a translatable therapeutic strategy.
References
- Loffredo FS, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153(4):828-839. https://pubmed.ncbi.nlm.nih.gov/23663781/
- Sinha M, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344(6184):649-652. https://pubmed.ncbi.nlm.nih.gov/24797481/
- Katsimpardi L, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344(6184):630-634. https://pubmed.ncbi.nlm.nih.gov/24797482/
- Egerman MA, et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 2015;22(1):164-174. https://pubmed.ncbi.nlm.nih.gov/26001423/